These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 30786040)
1. Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants. Ma J; Stingo FC; Hobbs BP Biom J; 2019 Jul; 61(4):902-917. PubMed ID: 30786040 [TBL] [Abstract][Full Text] [Related]
2. Bayesian predictive modeling for genomic based personalized treatment selection. Ma J; Stingo FC; Hobbs BP Biometrics; 2016 Jun; 72(2):575-83. PubMed ID: 26575856 [TBL] [Abstract][Full Text] [Related]
3. Estimating mean local posterior predictive benefit for biomarker-guided treatment strategies. Huang M; Hobbs BP Stat Methods Med Res; 2019 Sep; 28(9):2820-2833. PubMed ID: 30037304 [TBL] [Abstract][Full Text] [Related]
4. Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Ma J; Hobbs BP; Stingo FC Stat Methods Med Res; 2018 Jul; 27(7):2093-2113. PubMed ID: 27807177 [TBL] [Abstract][Full Text] [Related]
5. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis. Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P; BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898 [TBL] [Abstract][Full Text] [Related]
6. Identifying predictive markers for personalized treatment selection. Shen Y; Cai T Biometrics; 2016 Dec; 72(4):1017-1025. PubMed ID: 26999054 [TBL] [Abstract][Full Text] [Related]
7. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Gu X; Yin G; Lee JJ Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829 [TBL] [Abstract][Full Text] [Related]
8. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
9. Bayesian approach to incorporating different types of biomedical knowledge bases into information retrieval systems for clinical decision support in precision medicine. Balaneshinkordan S; Kotov A J Biomed Inform; 2019 Oct; 98():103238. PubMed ID: 31301513 [TBL] [Abstract][Full Text] [Related]
10. Borrowing strength with nonexchangeable priors over subpopulations. Leon-Novelo LG; Bekele BN; Müller P; Quintana F; Wathen K Biometrics; 2012 Jun; 68(2):550-8. PubMed ID: 22040065 [TBL] [Abstract][Full Text] [Related]
11. Personalized treatment selection via product partition models with covariates. Pedone M; Argiento R; Stingo FC Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364806 [TBL] [Abstract][Full Text] [Related]
12. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint. Adrion C; Mansmann U BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944 [TBL] [Abstract][Full Text] [Related]
13. Bayesian basket trial design with exchangeability monitoring. Hobbs BP; Landin R Stat Med; 2018 Nov; 37(25):3557-3572. PubMed ID: 29984488 [TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
15. A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability. Fujikawa K; Teramukai S; Yokota I; Daimon T Biom J; 2020 Mar; 62(2):330-338. PubMed ID: 31608505 [TBL] [Abstract][Full Text] [Related]
16. Designing and analyzing clinical trials for personalized medicine via Bayesian models. Zhang C; Mayo MS; Wick JA; Gajewski BJ Pharm Stat; 2021 May; 20(3):573-596. PubMed ID: 33463906 [TBL] [Abstract][Full Text] [Related]
17. Predictive model assessment for count data. Czado C; Gneiting T; Held L Biometrics; 2009 Dec; 65(4):1254-61. PubMed ID: 19432783 [TBL] [Abstract][Full Text] [Related]
18. Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identification. Zhao Y; Zheng W; Zhuo DY; Lu Y; Ma X; Liu H; Zeng Z; Laird G J Biopharm Stat; 2018; 28(3):534-549. PubMed ID: 29020511 [TBL] [Abstract][Full Text] [Related]
19. Goodness-of-fit diagnostics for Bayesian hierarchical models. Yuan Y; Johnson VE Biometrics; 2012 Mar; 68(1):156-64. PubMed ID: 22050079 [TBL] [Abstract][Full Text] [Related]
20. Bayesian data integration and variable selection for pan-cancer survival prediction using protein expression data. Maity AK; Bhattacharya A; Mallick BK; Baladandayuthapani V Biometrics; 2020 Mar; 76(1):316-325. PubMed ID: 31393003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]